{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:09:42Z","timestamp":1791482982767,"version":"4.3.4"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Syst. Biol."],"abstract":"<jats:p>Cervical-cancer genomic studies nominate many altered genes, but the evidence needed to distinguish disease association from a causal, therapeutically tractable mechanism is rarely stated explicitly. We present the Causal Integration Ladder (CIL), an evidence-accounting framework that distinguishes Level I association, inherited Level II-G evidence, acquired Level II-S evidence, Level III computational and direct functional evidence, and Level IV translational validation, while treating viral etiology as an explicit context modifier. An exploratory TCGA-CESC screen (306 tumours, 3 normal samples) supplied 25 Level I candidates. HPV annotations were available for 291 primary tumours (280 positive, 9 negative, 2 indeterminate). Restriction to HPV-positive tumours preserved the direction of all 25 Level I effects; HPV-positive versus HPV-negative comparisons were exploratory because the negative group was small and histologically heterogeneous. Somatic analysis used 194 mutation-evaluable and 295 copy-number-evaluable tumours. Ten candidates showed false-discovery-rate-significant copy-number\u2013expression associations, including CDKN2A, whereas recurrent protein-altering mutation was uncommon. Eight genes were additionally audited using public cis-eQTL, GWAS, dependency, pharmacogenomic, and cell-compartment resources. The revised CIL reports inherited, somatic, etiological, and functional evidence independently; absence of germline support is not interpreted as evidence against somatic, viral, or functional relevance. No observational result is presented as experimental validation, and Level III direct perturbation and Level IV translational claims remain prospective.<\/jats:p>","DOI":"10.3389\/fsysb.2026.1874355","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:30:24Z","timestamp":1789705824000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The causal integration ladder: a multilevel evidence framework for therapeutic target evaluation in cervical cancer"],"prefix":"10.3389","volume":"6","author":[{"given":"Shishir","family":"Singh","sequence":"first","affiliation":[{"name":"Division of Immunobiology, Cincinnati Children\u2019s Hospital Medical Center","place":["Cincinnati, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manyata","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Biosciences, Manipal University Jaipur","place":["Jaipur, Rajasthan, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragathi","family":"Uppada","sequence":"additional","affiliation":[{"name":"Department of Biosciences, Manipal University Jaipur","place":["Jaipur, Rajasthan, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diksha","family":"Ameta","sequence":"additional","affiliation":[{"name":"Department of Biosciences, Manipal University Jaipur","place":["Jaipur, Rajasthan, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aesha","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Marshall University","place":["Huntington, WV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monisha","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Department of Zoology,University of Lucknow","place":["Lucknow, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atar Singh","family":"Kushwah","sequence":"additional","affiliation":[{"name":"Department of Biosciences, Manipal University Jaipur","place":["Jaipur, Rajasthan, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","article-title":"The present and future of the cancer dependency map","volume":"25","author":"Arafeh","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","article-title":"Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens","volume":"568","author":"Behan","year":"2019","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"D886","DOI":"10.1093\/nar\/gkae1142","article-title":"CZ CELLxGENE discover: a single-cell data platform for scalable exploration, analysis and modeling of aggregated data","volume":"53","author":"Abdulla","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1093\/hmg\/ddu328","article-title":"Mendelian randomization: genetic anchors for causal inference in epidemiological studies","volume":"23","author":"Davey Smith","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"B6","unstructured":"DepMap portal. DepMap portal\n          \n          \n          2026"},{"key":"B7","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3892\/mmr.2021.11961","article-title":"miR-302c-3p and miR-520a-3p suppress the proliferation of cervical carcinoma cells by targeting CXCL8","volume":"23","author":"Ding","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"W697","DOI":"10.1093\/nar\/gkac328","article-title":"SigCom LINCS: data and metadata search engine for a million gene expression signatures","volume":"50","author":"Evangelista","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e1004383","DOI":"10.1371\/journal.pgen.1004383","article-title":"Bayesian test for colocalisation between pairs of genetic association studies using summary statistics","volume":"10","author":"Giambartolomei","year":"2014","journal-title":"PLoS Genet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"15159","DOI":"10.1007\/s00432-023-05305-w","article-title":"Genetic and epigenetic alterations in MGMT gene and correlation with concomitant chemoradiotherapy (CRT) in cervical cancer","volume":"149","author":"Gupta","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","article-title":"A landscape of pharmacogenomic interactions in cancer","volume":"166","author":"Iorio","year":"2016","journal-title":"Cell."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.3802\/jgo.2021.32.e72","article-title":"Significance of serum CA125 level in surgically resected cervical adenocarcinoma with adverse features","volume":"32","author":"Kim","year":"2021","journal-title":"J. Gynecol. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.53730\/ijhs.v6nS8.12025","article-title":"Anthro-demographic, clinico-pathological and biochemical risk factors in cervical cancer","volume":"6","author":"Kushwah","year":"2022","journal-title":"Int. J. Health Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"320","DOI":"10.2174\/1573394719666230807161948","article-title":"Impact of human papillomavirus (HPV) infection on the treatment outcome of concomitant chemoradiotherapy (CRT) in cervical cancer","volume":"20","author":"Kushwah","year":"2024","journal-title":"CCTR"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.1038\/s41467-018-06916-5","article-title":"Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration","volume":"9","author":"McFarland","year":"2018","journal-title":"Nat. Commun."},{"key":"B16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.virusres.2009.06.008","article-title":"Oncogenic activities of human papillomaviruses","volume":"143","author":"McLaughlin-Drubin","year":"2009","journal-title":"Virus Res."},{"key":"B17","unstructured":"Model context protocol specification, version 2026-07-28\n          \n          \n          2026"},{"key":"B18","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2886","article-title":"Human papillomavirus oncoproteins: pathways to transformation","volume":"10","author":"Moody","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"D1353","DOI":"10.1093\/nar\/gkac1046","article-title":"The next-generation open targets platform: reimagined, redesigned, rebuilt","volume":"51","author":"Ochoa","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e1008468","DOI":"10.1371\/journal.ppat.1008468","article-title":"Human papillomavirus E7 binds Oct4 and regulates its activity in HPV-associated cervical cancers","volume":"16","author":"Panayiotou","year":"2020","journal-title":"PLoS Pathog."},{"key":"B21","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41576-018-0020-3","article-title":"Using genetic data to strengthen causal inference in observational research","volume":"19","author":"Pingault","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"a040493","DOI":"10.1101\/cshperspect.a040493","article-title":"Causal inference methods to integrate omics and complex traits","volume":"11","author":"Porcu","year":"2021","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e3257","DOI":"10.1002\/jgm.3257","article-title":"miR-587 promotes cervical cancer by repressing interferon regulatory factor 6","volume":"22","author":"Ren","year":"2020","journal-title":"J. Gene Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"R149","DOI":"10.1093\/hmg\/ddw197","article-title":"Challenges and novel approaches for investigating molecular mediation","volume":"25","author":"Richmond","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1002335","DOI":"10.37349\/etat.2025.1002335","article-title":"Genetic and epigenetic landscape of O6-methylguanine-DNA methyltransferase (MGMT): implications for DNA repair and cancer therapeutics","volume":"6","author":"Singh","year":"2025","journal-title":"Explor Target Antitumor Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"D977","DOI":"10.1093\/nar\/gkac1010","article-title":"The NHGRI-EBI GWAS catalog: knowledgebase and deposition resource","volume":"51","author":"Sollis","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"The cancer genome atlas pan-cancer analysis project","volume":"45","author":"Weinstein","year":"2013","journal-title":"Nat. Genet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nature21386","article-title":"Albert einstein college of medicine analytical biological services barretos cancer hospital baylor college of medicine beckman research institute of city of hope integrated genomic and molecular characterization of cervical cancer","volume":"543","year":"2017","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.aaz1776","article-title":"The GTEx consortium atlas of genetic regulatory effects across human tissues","volume":"369","author":"Aguet","year":"2020","journal-title":"Science"},{"key":"B31","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell."},{"key":"B32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Systems Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsysb.2026.1874355\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:30:33Z","timestamp":1789705833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsysb.2026.1874355\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":32,"alternative-id":["10.3389\/fsysb.2026.1874355"],"URL":"https:\/\/doi.org\/10.3389\/fsysb.2026.1874355","relation":{},"ISSN":["2674-0702"],"issn-type":[{"value":"2674-0702","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1874355"}}